AI Article Synopsis

  • The study examined the IL-2 response and production in 9 men with AIDS and 28 men with PGL, all of whom were seropositive for HTLV-III/LAV.
  • Both groups showed significantly reduced T lymphocyte proliferation in response to IL-2 compared to seronegative controls, with T4+ and T8+ cells displaying specific deficiencies.
  • IL-2 production was also significantly lower in both AIDS (0.1 U/ml) and PGL (1.0 U/ml) groups compared to healthy controls (9.9 U/ml), indicating serious defects in the IL-2-T-lymphocyte system that may contribute to reduced T-lymphocyte function in these diseases.

Article Abstract

Proliferative responsiveness to, and production of, interleukin 2 (IL-2) was determined in 9 homosexually active men with the acquired immunodeficiency syndrome (AIDS) and in 28 homosexually active men with the persistent generalized lymphadenopathy syndrome (PGL). All were seropositive for antibody to human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). Purified T lymphocytes from individuals with AIDS and PGL had a significantly decreased (P less than 0.01) proliferative response to a saturating amount of exogenous, purified IL-2 as compared to seronegative male controls. Similarly, T4+-enriched T lymphocytes also had a significantly decreased proliferative responsiveness to IL-2 (AIDS, P less than 0.05; PGL, P less than 0.005). T8+-enriched T lymphocytes from individuals with AIDS or PGL did not suppress the IL-2-induced proliferation of autologous T4+ T lymphocytes. In addition, production of IL-2 was significantly decreased in the AIDS group (P less than 0.01) and the PGL group (P less than 0.005) with median values of IL-2 produced being 0.1 and 1.0 U/ml, respectively, compared to 9.9 U/ml for control. These findings demonstrate that substantial quantitative and qualitative abnormalities of the IL-2-T-lymphocyte system exist in patients with AIDS as well as in relatively healthy individuals with PGL. These defects are likely important contributing factors to the depressed T-lymphocyte functions commonly observed in HTLV-III/LAV-associated diseases.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0008-8749(87)90015-3DOI Listing

Publication Analysis

Top Keywords

acquired immunodeficiency
8
immunodeficiency syndrome
8
generalized lymphadenopathy
8
lymphadenopathy syndrome
8
proliferative responsiveness
8
homosexually active
8
active men
8
lymphocytes individuals
8
individuals aids
8
aids pgl
8

Similar Publications

HIV-1 envelope broadly neutralizing antibodies represent a promising component of HIV-1 cure strategies. To evaluate the therapeutic efficacy of combination monoclonal antibodies (mAbs) in a rigorous nonhuman primate model, we tested different combinations of simian immunodeficiency virus (SIV) neutralizing mAbs in SIVmac251-infected rhesus macaques. Antiretroviral therapy-suppressed animals received anti-SIV mAbs targeting multiple Env epitopes spanning analytical treatment interruption (ATI) in 3 groups (n = 7 each): i) no mAb; ii) 4-mAb combination; and iii) 2-mAb combination.

View Article and Find Full Text PDF

Background: Indonesia's vast archipelago and substantial population size present unique challenges in addressing its multifaceted HIV epidemic, with 90% of its 514 districts and cities reporting cases. Identifying key populations (KPs) is essential for effectively targeting interventions and allocating resources to address the changing dynamics of the epidemic.

Objective: We examine the 2022 mapping of Indonesia's KPs to develop improved HIV and AIDS interventions.

View Article and Find Full Text PDF

, the bacteria that causes syphilis, is typically acquired through sexual contact but can also be transmitted transplacentally (through the placenta), causing congenital infection. Syphilis in pregnancy is a major contributing factor to perinatal morbidity and mortality. Untreated neonates may develop complications affecting the central nervous system, bones, joints, teeth, eyes, and skin.

View Article and Find Full Text PDF

Designing and employing enzyme inhibitors against viral enzymes is one of the innovative and efficient approaches to treating viral diseases. These inhibitors can disrupt the viral replication cycle by deactivating vital enzymes, thereby curbing the spread of viral infections by reducing their population. So far, inhibitors have been designed, validated, and introduced for these enzymes.

View Article and Find Full Text PDF

The most significant progress in addressing the HIV/AIDS epidemic has been the development of antiretroviral therapy (ART). However, ensuring a high degree of treatment adherence is necessary to prevent resistance and disease progression. We conducted a cross-sectional study to evaluate adherence to ART through the calculation of the medication possession ratio (MPR) and to identify risk factors for suboptimal adherence in a cohort of HIV-positive patients receiving care at a Colombian healthcare institution across 16 cities.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!